BB Healthcare Share Chat (BBH)

Find Your Broker

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
BB Healthcare	LSE:BBH	London	Ordinary Share	GB00BZCNLL95	RED ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	135.00p	132.50p	135.50p	136.00p	132.50p	135.00p	387,901	16:35:25

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Health Care Equipment & Services	1.9	0.7	0.2	642.9	422.66

BB Healthcare Share Discussion Threads

Showing 51 to 74 of 75 messages

Chat Pages: 3 2 1

Date	Subject	Author	Discuss
06/11/2018 08:50	Thankls Eberhardt - if you register you get two free articles a week (that's good enough for me usually: BB Healthcare Trust reckons last month’s market sell-off is too much of an opportunity to miss. The investment trust pressed ahead with a share issue programme yesterday that could mean it raises more than its current market value over the next 12 months. It argued that the October fall in prices had a disproportionately high effect on the kinds of smaller, high-growth companies it invests in and there are stockpicking deals to be had. BB Healthcare may actually be one itself. Its shares have lost 9 per cent since the beginning of October, against a drop of 4.5 per cent in the wider MSCI Healthcare index that it benchmarks itself against. The company is worth a closer look. BB Healthcare was listed in December 2016 and is managed by Bellevue Asset Management, a Swiss-based group that came up with the idea of a specialist healthcare investment trust after it encountered investment constraints with an existing, much larger biotech fund. Its brief is to invest in listed healthcare companies worldwide based on no criteria other than potential future value. It has limited itself to a maximum of 35 holdings and in practice 94 per cent of its portfolio is with American companies, hardly surprising given the entrepreneurial role of the private sector in healthcare provision with a regulator that is keen to foster innovation in treatments. Among its largest investments is Anthem, a health insurance company formerly known as Wellpoint; Teladoc, a phone-based healthcare provider; and Illumina, a technology-driven group whose products are used in genetic analysis. The fund tries to ensure all of its funds are invested at any one time but regularly issues new stock to fund growth, unafraid to quadruple its size in the coming years from its current £430 million. Its facility yesterday authorised it to issue as many as 345 million new shares over the next 12 months, worth a little more than £470 million, based on yesterday’s price, up 1p to 135½p. Its strategy of investing in huge structural changes in worldwide health provision against the backdrop of our longer lives, better treatments for chronic diseases and the rise of private care is interesting. ADVICE Buy for the long term WHY Proven in profiting from healthcare’s structural changes	jonwig	Read Full Thread Reply
06/11/2018 08:35	According Tempus in The Times today BBH is a buy for the long term. Not a subscriber so can't give full link. Reported in the news summary in Citywire hxxps://citywire.co.uk/money/tuesday-papers-brussels-to-offer-border-compromise/a1172662?ref=citywire-money-latest-news-list	eberhardt	Read Full Thread Reply
05/11/2018 07:09	Issue of equity, including placing, open offer, intermediaries offer: https://www.investegate.co.uk/bb-healthcare-trust--bbh-/rns/issue-of-equity/201811050700052672G/ "The issue price per Ordinary Share of any shares issued pursuant to the Initial Issue will be at a premium of 2% to the unaudited NAV per Ordinary Share (cum income) on the day that the Initial Placing closes, which is expected to be 28 November 2018. "	jonwig	Read Full Thread Reply
28/8/2018 09:10	Woodford's mistake was taking big stakes in small companies, then getting stuck and unable to unload his losers. His stock-picking skills are poor, though.	jonwig	Read Full Thread Reply
28/8/2018 08:55	At the moment.....?	semper vigilans	Read Full Thread Reply
28/8/2018 08:52	they are too small for BBH	toffeeman	Read Full Thread Reply
28/8/2018 08:09	Would be good for all concerned if BBH invested in AGL & AOR if it hasn’t done so already. Performance v. good anyway!	semper vigilans	Read Full Thread Reply
11/5/2018 19:09	FT maybe explains recent strength: Ater a brief wobble, drug stocks are moving broadly higher on Friday as US President Donald Trump unveiled plans to keep a lid on rising prices, primarily by targeting foreign countries he claims have been freeloading off American research and development. Among the movers: • The S&P 500 healthcare sector is now up 1.2 per cent after briefly dipping into negative territory at the start of the speech. • Pharmacy chain CVS is up 1.7 per cent, and Walgreens is up 0.2 per cent. • Healthcare services company Cardinal Health is up 1.17 per cent, McKesson is up 1.7 per cent, Express Scripts is up 2.86 per cent and AmerisourceBergen is up 1.87 per cent • Drugmaker AbbVie is up 1.13 per cent, Pfizer is up 1.3 per cent, Merck is up 2.26 per cent, Bristol-Myers Squibb is up 1.17 per cent • The Nasdaq biotechnology index is up 2.2 per cent, and biotech company Regeneron is up 7 per cent.	jonwig	Read Full Thread Reply
09/4/2018 12:51	Factsheet out. Problems? Politics, mainly!	jonwig	Read Full Thread Reply
04/4/2018 05:42	@ Toffee - dunno: March factsheet is due any day now. US markets aren't looking good.	jonwig	Read Full Thread Reply
03/4/2018 19:54	Now trading below Nav (for the first time I think).Someat oop?	toffeeman	Read Full Thread Reply
16/2/2018 06:54	Comment on BBH after the annual results: Http://citywire.co.uk/investment-trust-insider/news/bb-healthcare-relieved-us-reforms-off-republican-agenda/a1092177?ref=investment-trust-insider-latest-news-list Maybe answers your question, Toffeeman!	jonwig	Read Full Thread Reply
01/2/2018 16:23	Bit of a grim few days - is this pre-bear market?	toffeeman	Read Full Thread Reply
24/10/2017 05:24	BBH a part of this article: Http://citywire.co.uk/investment-trust-insider/news/james-carthew-don-t-let-biopharma-s-slow-start-give-you-the-wrong-impression/a1061739?ref=investment-trust-insider-latest-news-list	jonwig	Read Full Thread Reply
21/9/2017 06:10	Result of issue: 57,224,047 new shares at 112.1p.	jonwig	Read Full Thread Reply
20/9/2017 10:37	We have an up-to-date NAV for last night: 110.48p, so issue price should be 112.14p.	jonwig	Read Full Thread Reply
20/9/2017 09:00	Interview: Http://citywire.co.uk/investment-trust-insider/news/beware-dividend-dangers-warns-bb-healthcare/a1050407?ref=investment-trust-insider-latest-news-list	jonwig	Read Full Thread Reply
19/9/2017 06:39	Latest NAV 111p so new shares would notionally be offered at ~112.7p. But if NAV fall is due to USD, it could continue and the offer overtaken by events. Can probably wait until noon tomorrow as unlikely to be over-subscribed, I think. Issue price is determined as cum-inc NAV at today's close plus 1.5%. Unfortunately that won't be published until mid-afternoon tomorrow, so best estimate is yesterday's closing NAV to be published this afternoon.	jonwig	Read Full Thread Reply
14/9/2017 17:49	A 1.5% mark-up on the latest NAV would put the offer price in the range 116.8 - 116.9p, which is just about what you can buy them for in the market. Anyone who wants a big chunk might take it up, but I'm unsure of the attraction.	jonwig	Read Full Thread Reply
13/9/2017 19:09	Page 12: The price at which new Ordinary Shares will be issued pursuant to the Second Issue will be calculated by reference to the prevailing NAV (cumincome) of the existing Ordinary Shares together with a premium of 1.5 per cent. intended to cover the costs and expenses of the Second Issue (including, without limitation, placing commissions). However, for illustrative purposes only, assuming that 25,484,200 Ordinary Shares are issued pursuant to the Second Issue and an issue price of 117.72 pence per new Ordinary Share ... Page 14: Under the Intermediaries Offer, the Ordinary Shares are being offered to Intermediaries in the United Kingdom, the Channel Islands and the Isle of Man who will facilitate the participation of their retail investor clients located in the United Kingdom, the Channel Islands and the Isle of Man. A minimum subscription amount of £1,000 per Underlying Applicant will apply. Completed Applications from Intermediaries must be received by Peel Hunt no later than 3.00 p.m. on 20 September 2017.	jonwig	Read Full Thread Reply
13/9/2017 15:08	Thanks for that jon.I could well have missed that.	shauney2	Read Full Thread Reply
13/9/2017 14:58	Prospectus published. NAV above 115.2p now. Only until 20/09 to apply.	jonwig	Read Full Thread Reply
08/9/2017 10:58	Citywire seems to know that they are planning a fundraising up to £200m at a premium to NAV. On current numbers, that suggests a price between 114.6p and 117p.I'd be quite keen to participate in that.	jonwig	Read Full Thread Reply
23/6/2017 16:42	Shares issued at a premium. Simple example: 1 share exists, assets 100, so nav 100. Add 1 new share at price of 105. So now 2 shares with assets 205, nav 102.5. Underlying investments haven't moved. That shows the arithmetic. Effect is smaller in real situations.	jonwig	Read Full Thread Reply

Chat Pages: 3 2 1